

Table no.	Title	Page no.
Chapter 2		
2.1	Techniques to overcome BBB barrier	21
2.2	Method of preparation of albumin nanoparticles	26
2.3	Application of albumin nanocarriers in cancer therapy	29
2.4	Clinically approved albumin nanocarriers for therapy and diagnosis of cancer and other diseases and ongoing clinical trials for cancer therapy	38
2.5	List of albumin nanoparticles in recent clinical trials	41
2.6	Application of HA as targeting ligand	45
2.7	Application of CS as targeting ligand	47
2.8	Application of Lf as targeting ligand	49
2.9	Currently Developed Nanocarriers for TMZ Delivery	55
2.10	Currently developed nanocarriers for delivery of LND	63
Chapter 3		
3.1	Calibration curve of TMZ in DD water by UV-visible spectrophotometer	82
3.2	Calibration data of TMZ in DD water	82
3.3	Calibration curve of TMZ in acetate buffer (pH 5.5) by UV-visible spectrophotometer	83
3.4	Calibration data of TMZ in acetate buffer pH 5.5	84
3.5	Calibration curve of TMZ in plasma by SALLE-HPLC	84
3.6	Calibration data of TMZ in plasma by SALLE-HPLC	85
3.7	Calibration curve of TMZ in plasma by HPLC method II	84
3.8	Calibration data of TMZ in plasma by HPLC method II	86
3.9	Calibration curve of TMZ in brain homogenate by HPLC method II	86
3.10	Calibration data of TMZ in brain homogenate HPLC method II	87
3.11	Calibration curve of LND in methanol: water (50:50) by UV-visible spectrophotometer	88
3.12	Calibration data of LND in methanol: water (50:50)	88
3.13	Calibration curve of LND in PBS 7.4 by Spectrofluorophotometer	90

3.14	Calibration data of LND in PBS pH 7.4	91
3.15	Calibration curve of LND in phosphate buffer pH 5.5 by Spectrofluorophotometer	91
3.16	Calibration data of LND in phosphate buffer pH 5.5	91
3.17	Calibration curve of HA by CTAB turbidimetric method	92
3.18	Calibration data of HA by CTAB turbidimetric method	92
3.19	Calibration curve of CS by CTAB turbidimetric method	93
3.20	Calibration data of CS by CTAB turbidimetric method	93
3.21	Calibration curve of Lf using Bradford protein assay	95
3.22	Calibration data of Lf using Bradford protein assay	95
3.23	Calibration curve of BSA using Bradford protein assay	96
3.24	Calibration data of BSA using Bradford protein assay	96
Chapter 4		
4.1	Interpretation of FTIR spectrum of TMZ	102
4.2	Interpretation of FTIR spectrum of LND	103
4.3	Stability of TMZ in different solvents	108
Chapter 5		
5.1	Effect of albumin concentration	118
5.2	Effect of solvent and pH of aqueous phase	119
5.3	Effect of aqueous to organic phase ratio	121
5.4	Effect of organic solvent	122
5.5	Effect of gluteraldehyde concentration	123
5.6	Effect of rate of addition of organic phase	125
5.7	Effect of polymer to drug ratio	126
5.8	Working range of different variables after preliminary optimization	127
5.9	Optimization of TNPs using BBD	128
5.10	Predicted and obtained value for desirability plot for preparation of TNPs	137
5.11	Summary of absorption peaks of FTIR spectrum of TMZ, BSA, PNPs and TNPs	141
5.12	Stability studies of lyophilized TNPs	144

Chapter 6		
6.1	Effect of molecular weight of HA on conjugation	154
6.2	Effect of HA : NPs ratio on conjugation	154
6.3	Effect of stirring time on conjugation	155
6.4	Effect of CS: NPs ratio on conjugation	158
6.5	Effect of stirring time on conjugation	159
6.6	Stability studies of lyophilized HA-TNPs. Data is represented as mean \pm SD (n=3)	173
6.7	Stability studies of lyophilized CS-TNPs. Data is represented as mean \pm SD (n=3)	174
Chapter 8		
8.1	Pharmacokinetic parameters of TMZ, TNPs, HA-TNPs and CS-TNPs in rats (n=6). Data is represented as mean \pm SD	201
8.2	Biochemical parameter estimation after i.v administration of nanoparticles after 7 days. . Data is represented as mean \pm SD (n=6)	205
Chapter 9		
9.1	Effect of aqueous to organic phase ratio on particle size, PDI, % EE and % DL of LNPs	215
9.2	Effect of organic solvent on particle size, PDI, % EE and % DL of LNPs	216
9.3	Effect of amount of glutaraldehyde on particle size, PDI, % EE and % DL of LNPs	217
9.4	Effect of rate of addition of organic phase on particle size, PDI, % EE and % DL of LNPs	219
9.5	Effect of drug concentration on particle size, PDI, % EE and % DL of LNPs	220
9.6	Effect of drug concentration on particle size, PDI, % EE and % DL of LNPs	221
9.7	Optimized values of different variables after OFAT analysis	222
9.8	Effect of time of stirring on the coating of Lf over LNPs	223
9.9	Effect of Lf concentration	224
9.10	Summary of absorption peaks of FTIR spectrum of BSA, LND, LF, physical mixture, Lf-PNPs and Lf-LNPs	229

9.11	<i>In-vitro</i> drug release in phosphate buffer pH 7.4	234
9.12	Summary of modification efficiency of Lf on Lf-LNPs	234
9.13	Stability studies of lyophilized Lf-LNPs. Data is represented as mean \pm SD (n=3)	236
Chapter 11		
11.1	Changes in the tumor volume of untreated (model control), LND (standard control) and Lf-LNPs treated mice	252
11.2	Percent tumor growth of untreated (model control), pure LND (standard control) and Lf-LNPs treated mice.	253